研究园简易版
·
经典书籍
·
期刊文章
·
有原文
·
完整版(可多选筛选、搜索)
·
首页
搜索
2019 年 · Clinical Trials(临床试验)
97 篇,新的在前。点标题看作者和摘要。
回到 2019 年
Novel methods for the analysis of stepped wedge cluster randomized trials
· SiM · 2019-12-26 · 在第 1 页
G‐estimation of structural nested restricted mean time lost models to estimate effects of time‐varying treatments on a failure time outcome
· Biometrics · 2019-12-26 · 在第 1 页
Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker
· Biometrika · 2019-12-24 · 在第 1 页
Sample size and power for the weighted log‐rank test and Kaplan‐Meier based tests with allowance for nonproportional hazards
· Biometrics · 2019-12-23 · 在第 1 页
Improving safety of the continual reassessment method via a modified allocation rule
· SiM · 2019-12-20 · 在第 1 页
Randomization tests for multiarmed randomized clinical trials
· SiM · 2019-12-17 · 在第 1 页
Exact tests using binary data in adaptive two or multi-stage designs
· SMMR · 2019-12-09 · 在第 2 页
A surrogateℓ0sparse Cox's regression with applications to sparse high‐dimensional massive sample size time‐to‐event data
· SiM · 2019-12-08 · 在第 2 页
Optimizing interim analysis timing for Bayesian adaptive commensurate designs
· SiM · 2019-12-04 · 在第 2 页
Design and analysis considerations for cohort stepped wedge cluster randomized trials with a decay correlation structure
· SiM · 2019-12-04 · 在第 2 页
Incorporating patient‐reported outcomes in dose‐finding clinical trials
· SiM · 2019-12-03 · 在第 2 页
Joint modeling of binary response and survival for clustered data in clinical trials
· SiM · 2019-11-28 · 在第 3 页
Adaptive trial designs in diagnostic accuracy research
· SiM · 2019-11-27 · 在第 3 页
Cancer immunotherapy trial design with cure rate and delayed treatment effect
· SiM · 2019-11-26 · 在第 3 页
An adaptive power prior for sequential clinical trials – Application to bridging studies
· SMMR · 2019-11-15 · 在第 4 页
Power calculation for cross‐sectional stepped wedge cluster randomized trials with variable cluster sizes
· Biometrics · 2019-11-14 · 在第 4 页
Missing data and sensitivity analysis for binary data with implications for sample size and power of randomized clinical trials
· SiM · 2019-11-14 · 在第 4 页
Bayesian design of biosimilars clinical programs involving multiple therapeutic indications
· Biometrics · 2019-11-11 · 在第 4 页
How many times should a cluster randomized crossover trial cross over?
· SiM · 2019-11-10 · 在第 4 页
Designing precision medicine trials to yield a greater population impact
· Biometrics · 2019-11-07 · 在第 5 页
Confidence interval estimation for the changepoint of treatment stratification in the presence of a qualitative covariate‐treatment interaction
· SiM · 2019-11-07 · 在第 5 页
Sample size calculation for clinical trials with correlated count measurements based on the negative binomial distribution
· SiM · 2019-10-25 · 在第 6 页
Noninferiority testing for matched‐pair ordinal data with misclassification
· SiM · 2019-10-21 · 在第 6 页
Evaluating futility of a binary clinical endpoint using early read‐outs
· SiM · 2019-10-20 · 在第 6 页
Two‐stage enrichment clinical trial design with adjustment for misclassification in predictive biomarkers
· SiM · 2019-10-17 · 在第 6 页
Multi‐stage enrichment and basket trial designs with population selection
· SiM · 2019-10-17 · 在第 6 页
Assessing the ratio of means as a causal estimand in clinical endpoint bioequivalence studies in the presence of intercurrent events
· SiM · 2019-10-17 · 在第 6 页
A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
· SiM · 2019-10-17 · 在第 6 页
Two-level approaches to missing data in longitudinal trials with daily patient-reported outcomes
· SMMR · 2019-10-09 · 在第 7 页
What are the statistical implications of treatment non‐compliance in cluster randomized trials: A simulation study
· SiM · 2019-10-03 · 在第 7 页
Sample size considerations for comparing dynamic treatment regimens in a sequential multiple-assignment randomized trial with a continuous longitudinal outcome
· SMMR · 2019-10-01 · 在第 7 页
Group sequential design for time-to-event data using the concept of proportional time
· SMMR · 2019-10-01 · 在第 7 页
Testing multiple dose combinations in clinical trials
· SMMR · 2019-09-24 · 在第 8 页
A variational approach to optimal two‐stage designs
· SiM · 2019-09-20 · 在第 8 页
An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes
· Biometrics · 2019-09-19 · 在第 8 页
A response‐adaptive randomization procedure for multi‐armed clinical trials with normally distributed outcomes
· Biometrics · 2019-09-19 · 在第 8 页
Quantification of prior impact in terms of effective current sample size
· Biometrics · 2019-09-13 · 在第 8 页
Adaptive treatment allocation for comparative clinical studies with recurrent events data
· Biometrics · 2019-09-12 · 在第 8 页
On construction of smallest one-sided confidence intervals for the response rate in adaptive two- or multi-stage designs
· SMMR · 2019-09-05 · 在第 9 页
Measurement error in continuous endpoints in randomised trials: Problems and solutions
· SiM · 2019-09-02 · 在第 9 页
Adaptive designs in multi-reader multi-case clinical trials of imaging devices
· SMMR · 2019-08-28 · 在第 9 页
On estimands arising from misspecified semiparametric rate‐based analysis of recurrent episodic conditions
· SiM · 2019-08-20 · 在第 9 页
Sample size calculation for the Andersen‐Gill model comparing rates of recurrent events
· SiM · 2019-08-09 · 在第 10 页
Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrence
· SiM · 2019-08-06 · 在第 10 页
On the analysis of two‐phase designs in cluster‐correlated data settings
· SiM · 2019-07-29 · 在第 11 页
Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study
· SMMR · 2019-07-29 · 在第 11 页
Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease
· SiM · 2019-07-23 · 在第 11 页
An additive boundary for group sequential designs with connection to conditional error
· SiM · 2019-07-23 · 在第 11 页
Information content of stepped‐wedge designs when treatment effect heterogeneity and/or implementation periods are present
· SiM · 2019-07-18 · 在第 11 页
Properties and pitfalls of weighting as an alternative to multilevel multiple imputation in cluster randomized trials with missing binary outcomes under covariate-dependent missingness
· SMMR · 2019-07-11 · 在第 12 页
Bayesian consensus‐based sample size criteria for binomial proportions
· SiM · 2019-07-11 · 在第 12 页
Joint modeling of progression‐free and overall survival and computation of correlation measures
· SiM · 2019-07-04 · 在第 12 页
Adding dose modifications into Phase II and Phase II/III seamless trials
· SMMR · 2019-07-03 · 在第 12 页
Comparison of novel methods in two‐way enriched clinical trial design
· SiM · 2019-06-30 · 在第 12 页
Combined criteria for dose optimisation in early phase clinical trials
· SiM · 2019-06-27 · 在第 13 页
Frequentist operating characteristics of Bayesian optimal designs via simulation
· SiM · 2019-06-19 · 在第 13 页
Adaptive group‐sequential design with population enrichment in phase 3 randomized controlled trials with two binary co‐primary endpoints
· SiM · 2019-06-11 · 在第 14 页
Investigating protein patterns in human leukemia cell line experiments: A Bayesian approach for extremely small sample sizes
· SMMR · 2019-06-07 · 在第 14 页
Dose optimisation with simultaneous pharmacokinetic estimation in adaptive clinical trials
· SMMR · 2019-06-07 · 在第 14 页
The population‐attributable fraction for time‐dependent exposures and competing risks—A discussion on estimands
· SiM · 2019-06-04 · 在第 14 页
Subgroup identification using covariate‐adjusted interaction trees
· SiM · 2019-06-04 · 在第 14 页
Optimal designs in three‐level cluster randomized trials with a binary outcome
· SiM · 2019-06-04 · 在第 14 页
Estimating cluster-level local average treatment effects in cluster randomised trials with non-adherence
· SMMR · 2019-05-24 · 在第 16 页
To add or not to add a new treatment arm to a multiarm study: A decision‐theoretic framework
· SiM · 2019-05-21 · 在第 16 页
Design and analysis of stratified clinical trials in the presence of bias
· SMMR · 2019-05-10 · 在第 16 页
A multi-treatment response adaptive design for ordinal categorical responses
· SMMR · 2019-05-10 · 在第 16 页
Bayesian hierarchical EMAX model for dose‐response in early phase efficacy clinical trials
· SiM · 2019-05-09 · 在第 16 页
A note on sample size calculations for cluster randomised crossover trials with a fixed number of clusters
· SiM · 2019-05-08 · 在第 16 页
A conditional error function approach for adaptive enrichment designs with continuous endpoints
· SiM · 2019-05-07 · 在第 17 页
Implementing unequal randomization in clinical trials with heterogeneous treatment costs
· SiM · 2019-05-03 · 在第 17 页
Sample size considerations for stratified cluster randomization design with binary outcomes and varying cluster size
· SiM · 2019-04-29 · 在第 17 页
Quantile regression and empirical likelihood for the analysis of longitudinal data with monotone missing responses due to dropout, with applications to quality of life measurements from clinical trials
· SiM · 2019-04-17 · 在第 18 页
One‐step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure‐time endpoints
· SiM · 2019-04-17 · 在第 19 页
A Bayesian adaptive marker‐stratified design for molecularly targeted agents with customized hierarchical modeling
· SiM · 2019-04-09 · 在第 19 页
An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncology
· SMMR · 2019-04-04 · 在第 20 页
Randomised trials with provision for early stopping for benefit (or harm): The impact on the estimated treatment effect
· SiM · 2019-03-19 · 在第 21 页
Time Series Experiments and Causal Estimands: Exact Randomization Tests and Trading
· JASA · 2019-03-18 · 在第 21 页
Level of evidence for promising subgroup findings: The case of trends and multiple subgroups
· SiM · 2019-03-13 · 在第 21 页
Causal Inference With Interfering Units for Cluster and Population Level Treatment Allocation Programs
· Biometrics · 2019-03-11 · 在第 21 页
Augmented pseudo-likelihood estimation for two-phase studies
· SMMR · 2019-03-05 · 在第 22 页
A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints
· SMMR · 2019-02-25 · 在第 22 页
Nonparametric testing for multiple survival functions with noninferiority margins
· AoS · 2019-02-01 · 在第 23 页
Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis
· SMMR · 2019-01-30 · 在第 24 页
Efficient Methods for Signal Detection From Correlated Adverse Events in Clinical Trials
· Biometrics · 2019-01-28 · 在第 24 页
Alpha spending for historical versus surveillance Poisson data with CMaxSPRT
· SiM · 2019-01-28 · 在第 24 页
A Cluster-Adjusted Rank-Based Test for a Clinical Trial Concerning Multiple Endpoints With Application to Dietary Intervention Assessment
· Biometrics · 2019-01-28 · 在第 24 页
A Bayesian Hierarchical Model Estimating CACE in Meta-Analysis of Randomized Clinical Trials With Noncompliance
· Biometrics · 2019-01-28 · 在第 24 页
A novel confidence interval for a single proportion in the presence of clustered binary outcome data
· SMMR · 2019-01-23 · 在第 24 页
Re‐randomization tests in clinical trials
· SiM · 2019-01-22 · 在第 24 页
Accounting for a decaying correlation structure in cluster randomized trials with continuous recruitment
· SiM · 2019-01-21 · 在第 24 页
A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials
· SMMR · 2019-01-16 · 在第 24 页
A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components
· SiM · 2019-01-13 · 在第 25 页
Sample size considerations and predictive performance of multinomial logistic prediction models
· SiM · 2019-01-06 · 在第 25 页
Small-sample performance and underlying assumptions of a bootstrap-based inference method for a general analysis of covariance model with possibly heteroskedastic and nonnormal errors
· SMMR · 2019-01-02 · 在第 25 页
Robust inference for the stepped wedge design
· Biometrics · 2019 · 在第 27 页
Power in High‐Dimensional Testing Problems
· Econometrica · 2019 · 在第 27 页
Equivalence of regression curves sharing common parameters
· Biometrics · 2019 · 在第 29 页